[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360407-105":59,"doc-detail-360407-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeting-b7-h3-in-patients-with-metastatic-triple-negative-breast-cancer-and-brain-metastases-an-opportunity-to-revive-immunotherapy-as-a-treatment-strategy","Targeting B7-H3 in patients with metastatic triple-negative breast cancer and brain metastases - an opportunity to revive immunotherapy as a treatment strategy?","","Approximately one-third of patients with metastatic triple-negative breast cancer develop brain metastases during their lifetime, with up to 90% expressing B7-H3. B7-H3 is linked to an immunosuppressive microenvironment, correlating with regulatory T cells and inversely with CD8+ T cells. The article proposes B7-H3-targeted antibody-drug conjugates to convert “cold” tumors into “hot” tumors, improving immunotherapy responsiveness. It also summarizes eight phase I/II trials and argues for broader inclusion and further study of ADCs, including potential prevention of brain metastases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeting-b7-h3-in-patients-with-metastatic-triple-negative-breast-cancer-and-brain-metastases-an-opportunity-to-revive-immunotherapy-as-a-treatment-strategy/360407/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeting-b7-h3-in-patients-with-metastatic-triple-negative-breast-cancer-and-brain-metastases-an-opportunity-to-revive-immunotherapy-as-a-treatment-strategy/360407.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How common are brain metastases in metastatic triple-negative breast cancer?","Question",{"text":112,"@type":113},"About one-third of patients develop brain metastases during their lifetime. Up to 90% of TNBC brain metastases express B7-H3.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Why is B7-H3 a promising target for immunotherapy in this setting?",{"text":117,"@type":113},"B7-H3 is associated with an immunosuppressive tumor microenvironment, positively correlating with regulatory T cells and negatively with CD8+ T cells.",{"name":119,"@type":110,"acceptedAnswer":120},"What do the phase I/II trial findings suggest about patient selection for B7-H3 ADCs?",{"text":121,"@type":113},"A search identified eight phase I/II trials of B7-H3 ADCs; most include patients with asymptomatic brain metastases. The article argues future studies should broadly include patients with brain metastases and further evaluate ADCs for preventing brain metastases.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360407,1790395668,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":81,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":39,"preview_page_count":81,"preview_urls":144},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Open access Commentary  \n Targeting B7-H3 in patients with  \nmetastatic triple-negative breast cancer and brain metastases: an opportunity to“revive” immunotherapy as a treatment strategy?  \nIsabella Kojundzic,1,2 Cody Zatzman,1,2 Julia Belone Lopes,2,3 Rohma Ramay,2 Jane Bayani,4,5 Melanie Spears,4,5 Katarzyna J Jerzak2,3  \nTo cite: Kojundzic I, Zatzman C, Belone Lopes J, et al. Targeting B7-H3 in patients with metastatic triple-negative breast cancer and brain metastases: an opportunity to“revive” immunotherapy as a treatment strategy? Journal for ImmunoTherapy of Cancer 2026;14:e013907 . doi:10 . 1136/ jitc-2025-013907  \nAccepted 18 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada  \n2Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada  \n3Department of Medicine, University of Toronto, Toronto, Ontario, Canada  \n4Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Ontario, Canada  \n5Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada  \nCorrespondence to  \nDr Katarzyna J Jerzak;  \nkatarzyna.jerzak@sunnybrook. ca  \nABSTRACT  \nApproximately one-third of patients with metastatic triplenegative breast cancer (TNBC) develop brain metastases during their lifetime. Notably, up to 90% of TNBC brain metastases express B7-H3, a molecule that contributes to an immunosuppressive microenvironment—positively correlating with regulatory T cells and negatively  \nwith CD8+T cells. We propose that B7-H3-targeted antibody-drug conjugates (ADCs) may help convert these immunologically “cold” tumors into “hot” ones, thereby enhancing the responsiveness of patients with metastatic TNBC and brain metastases to immunotherapy. The ability of ADCs to penetrate a blood-brain barrier that is disrupted by brain metastases and/or associated local therapies generates considerable excitement for this potential approach.  \nWe further describe a search of the [clinicaltrials.gov](clinicaltrials.gov)[ ](clinicaltrials.gov)[website](website), [which yielded](which yielded) eight phase I/II trials examining the efficacy of B7-H3 ADCs, 12 .5%(n=1/8) of which exclude patients with brain metastases and 62.5%(n=5/8) of which include patients with asymptomatic brain metastases. Given the natural progression of metastatic TNBC and the high incidence of brain metastases, future studies of B7-H3-targeted therapies should consider the broad inclusion of patients with brain metastases. Additionally, the potential of B7-H3-targeted ADCs to prevent brain metastases warrants investigation in both preclinical models and clinical trials.  \nMAIN TEXT  \nBrain metastases occur in approximately one-third of patients with metastatic triplenegative breast cancer (mTNBC) and confer a poor prognosis, highlighting the need for novel therapeutic strategies in this population. Early immunotherapy clinical trials for patients with heavily pretreated and biomarker unselected metastatic breast cancer failed to demonstrate efficacy. However, when used in the first-line setting for patients with metastatic TNBC and programmed death-ligand 1 (PD-L1) positive disease, pembrolizumab in  \ncombination with chemotherapy significantly prolonged both progression-free (PFS) and overall survival. Although this is a significant advancement in standard-of-care therapy for patients with mTNBC, only ~40% of patients are candidates for immunotherapy based on expression of the predictive biomarker PD-L1 .1 Further, the activity of immunotherapy for patients with mTNBC and brain metastases remains under-explored. Less than 5% (n=33/750) of patients in the KEYNOTE-3552 and 7% (n=86/1271) in the IMpassion1303 clinical trials had stable treated brain metastases, respectively; and no patients with active brain metastases were included in eithe","cbCaimjzpmHWf3io","https://ap.wps.com/l/cbCaimjzpmHWf3io","pdf",171143,"English","# Abstract\n## Rationale for B7-H3 targeting\n## Clinical trial landscape and inclusion considerations\n# Main Text\n## Limitations of existing immunotherapy in brain metastases\n## Related trial experience and outcomes","[{\"question\":\"How common are brain metastases in metastatic triple-negative breast cancer?\",\"answer\":\"About one-third of patients develop brain metastases during their lifetime. Up to 90% of TNBC brain metastases express B7-H3.\"},{\"question\":\"Why is B7-H3 a promising target for immunotherapy in this setting?\",\"answer\":\"B7-H3 is associated with an immunosuppressive tumor microenvironment, positively correlating with regulatory T cells and negatively with CD8+ T cells.\"},{\"question\":\"What do the phase I/II trial findings suggest about patient selection for B7-H3 ADCs?\",\"answer\":\"A search identified eight phase I/II trials of B7-H3 ADCs; most include patients with asymptomatic brain metastases. The article argues future studies should broadly include patients with brain metastases and further evaluate ADCs for preventing brain metastases.\"}]","Targeting B7-H3 in patients with metastatic triple-negative breast cancer and brain metastases - an opportunity to revive immunotherapy as a treatment strategy? | PDF",1790139960,[145,149,153],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26ee00880766066bc4bb4f2ac5ecd9b5.webp",983,1310,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be3f0562f5d3f64f7edda445482b7923.webp",982,1309,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15a32705254a6e89409b6c75582a5327.webp",981,1308]